- Home
- ATYR vs PSNYW Comparison
ATYR vs PSNYW Comparison
Compare ATYR & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- PSNYW
- Stock Information
- Founded
- ATYR 2005
- PSNYW 2017
- Country
- ATYR United States
- PSNYW Sweden
- Employees
- ATYR N/A
- PSNYW 2547
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- PSNYW Auto Manufacturing
- Sector
- ATYR Health Care
- PSNYW Consumer Discretionary
- Exchange
- ATYR Nasdaq
- PSNYW Nasdaq
- Market Cap
- ATYR 451.3M
- PSNYW 348.4M
- IPO Year
- ATYR 2015
- PSNYW N/A
- Fundamental
- Price
- ATYR $4.94
- PSNYW $0.15
- Analyst Decision
- ATYR Strong Buy
- PSNYW
- Analyst Count
- ATYR 6
- PSNYW 0
- Target Price
- ATYR $20.20
- PSNYW N/A
- AVG Volume (30 Days)
- ATYR 5.8M
- PSNYW 43.4K
- Earning Date
- ATYR 08-12-2025
- PSNYW 03-06-2025
- Dividend Yield
- ATYR N/A
- PSNYW N/A
- EPS Growth
- ATYR N/A
- PSNYW N/A
- EPS
- ATYR N/A
- PSNYW N/A
- Revenue
- ATYR N/A
- PSNYW $2,034,261,000.00
- Revenue This Year
- ATYR $551.06
- PSNYW N/A
- Revenue Next Year
- ATYR $1,874.58
- PSNYW $79.49
- P/E Ratio
- ATYR N/A
- PSNYW N/A
- Revenue Growth
- ATYR N/A
- PSNYW N/A
- 52 Week Low
- ATYR $1.67
- PSNYW $0.09
- 52 Week High
- ATYR $7.29
- PSNYW $0.61
- Technical
- Relative Strength Index (RSI)
- ATYR 44.73
- PSNYW 47.16
- Support Level
- ATYR $5.46
- PSNYW $0.15
- Resistance Level
- ATYR $7.29
- PSNYW $0.17
- Average True Range (ATR)
- ATYR 0.66
- PSNYW 0.01
- MACD
- ATYR -0.09
- PSNYW -0.00
- Stochastic Oscillator
- ATYR 3.69
- PSNYW 35.57
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.